Disease · MONDO_0005141

Pseudomonas infection

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Pseudomonas infection. Diseases, record MONDO_0005141. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005141

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Pseudomonas infection; Open Targets
Open Targets ID: MONDO_0005141; Open Targets
Other names: Bacterial infection due to Pseudomonas, Bacterial infection due to Pseudomonas (disorder), Bacterial infectious disease due to Pseudomonas (disorder), INFECT PSEUDOMONAS, Infection, Pseudomonas, Infections, Pseudomonas, PSEUDOMONAS INFECT, Pseudomonas Infections, Pseudomonas caused disease or disorder, Pseudomonas disease or disorder, Pseudomonas infectious disease; Open Targets
MeSH: D011552; MeSH
Highest stage of its drugs: Approval, for 5 of its 12 drugs, from TTD; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZLOCILLIN	CHEMBL1537	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CEFSULODIN	CHEMBL3351077	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CHLORTETRACYCLINE	CHEMBL404520	Small molecule	Approval	TTD	1	0	0	Drugs and targets
COLISTIN	CHEMBL6067481		Approval	TTD	1	0	0	Drugs and targets
POLYMYXIN B SULFATE	CHEMBL5314355	Protein	Approval	TTD	1	0	0	Drugs and targets
PIPERACILLIN	CHEMBL702	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TAZOBACTAM	CHEMBL404	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM NITRITE	CHEMBL93268	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
PANOBACUMAB	CHEMBL1743055	Antibody	Phase 1/2	TTD	1	0	0	Drugs and targets
ACHN-975	CHEMBL3939284	Small molecule	Phase 1	TTD	1	0	0	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02694393	Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis	Phase 1/2	4	2024-06-24	Cystic Fibrosis	SODIUM NITRITE	Its record names the disease	ClinicalTrials.gov
NCT01577368	Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa	Phase 3	76		Pseudomonas Aeruginosa Infection	PIPERACILLIN, TAZOBACTAM	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005141

GET https://conductscience.org/api/diseases/v1/MONDO_0005141/drugs

API reference For AI assistants